Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist currently being researched for its interaction with appetite regulation, metabolic signaling, and glucose-related pathways. Research has focused on its potential role in supporting satiety signaling, energy balance, and digestive response mechanisms through combined incretin receptor activity.
Studies have also explored Tirzepatide’s relationship with body composition research, insulin signaling, and long-term metabolic regulation.
Common Research Uses
- Appetite regulation and satiety
- Dual incretin and metabolic signaling
- Gastric emptying and digestive response
- Body composition and weight management
Typical Research Dosing
Subcutaneous Protocol (30 mg + 2 mL BAC = 15 mg/mL)
| Phase | Weekly Dose (mg) | Units per Injection |
|---|---|---|
| Weeks 1-4 | 2.5 mg once weekly | 17 units |
| Weeks 5-8 | 5 mg once weekly | 33 units |
| Weeks 9-12 | 7.5 mg once weekly | 50 units |
| Weeks 13-16 | 10 mg once weekly | 67 units |
| Weeks 17-20 | 12.5 mg once weekly | 83 units |
| Weeks 21-24 | 15 mg once weekly | 100 units |
Based on reconstitution of 30 mg with 2 mL bacteriostatic water (15 mg/mL).
Reconstitution Steps
- Prep clean: Wash hands, use a clean surface, and gather supplies.
- Sanitize: Alcohol swab vial stoppers and allow to air-dry.
- Add diluent slowly: Inject bacteriostatic water down the vial wall to reduce foaming.
- Mix gently: Gently swirl or roll until fully dissolved. Do not shake.
- Label: Write compound name, date, and concentration (mg/mL).
- Store appropriately: Store according to supplier guidance and maintain sterile technique.
Educational reference only
Injection Technique
General subcutaneous guidance from clinical best-practice resources.
- Allow the peptide to reach room temperature before injection.
- Clean the vial stopper and injection site with alcohol and allow to fully dry.
- Pinch a small skinfold and insert the needle at a 45–90° angle into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate injection sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
- Inject slowly to help minimize any stinging sensation.
This information is provided for educational reference only and reflects general clinical best practices.
Recommended Source
We recommend MADDOG Peps for high-purity Tirzepatide (30 mg).
- High-purity lots with manufacturer-issued third-party COAs available upon request for transparency and quality reference.
- Consistent handling practices aligned with quality control standards.
- Reliable fulfillment, careful packaging, and fast UPS shipping to help maintain product integrity.
How It Works
Tirzepatide is a synthetic peptide designed to activate both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. These incretin hormones play important roles in regulating appetite, glucose metabolism, digestive activity, and energy balance.
Research suggests Tirzepatide works through dual receptor activity that may enhance satiety signaling, slow gastric emptying, and influence caloric intake pathways. Studies have focused on how combined GIP and GLP-1 receptor activation may produce complementary metabolic effects compared to targeting GLP-1 pathways alone.
At the cellular and systemic level, Tirzepatide has been studied for its influence on insulin signaling, glucagon regulation, nutrient utilization, and appetite-related neurological pathways. Researchers have also explored its potential impact on food reward signaling and long-term body composition changes.
Unlike stimulant-based metabolic compounds, Tirzepatide is being researched for its hormone-mimicking mechanism centered on incretin signaling and metabolic regulation rather than central nervous system stimulation.
Commonly Reported Side Effects
- Constipation
- Fatigue
- Vomiting
- Diarrhea
- Nausea
- Injection site reactions
These effects are based on commonly reported research observations and may vary by individual.